PURPOSE Ambrisentan (ABS) is an antihypertensive drug used in the treatment of pulmonary atrial hypertension. The survey of literature for ABS revealed only two spectrophotometric methods for its quantification. The reported methods lack the sensitivity. This study is aimed at developing two sensitive extractive spectrophotometric methods for the determination of ABS in bulk and in tablets. M...

5 Cader MZ, Filer A, Hazlehurst J et al. Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early syno-vitis cohort. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study SIR, SSc is characterized by fibrotic thickening of the skin and internal organs and widespread vascul...

Ambrisentan in 22 patients with pulmonary hypertension diagnosed during exercise (ePH) improved pulmonary hemodynamics; however, there was only a trend toward increased maximum oxygen uptake (VO2max) secondary to decreased maximum exercise systemic oxygen extraction (Ca-vO2). We speculate that improved pulmonary hemodynamics at maximum exercise "unmasked" a pre-existing skeletal muscle abnormal...

Evidence lacks on the differential effects of the two therapeutic concepts of endothelin receptor antagonists (ERA): the blockade of only the endothelin-receptorA (ETAR) (selective antagonism) versus both ETAR and ETBR (dual blockade). Ambrisentan, a selective ERA, and bosentan, a dual blocker, are both available for therapy. We hypothesized that there are differences in the potential of ERAs t...

Evidence is lacking on the differential effects of the two therapeutic concepts of endothelin receptor antagonists (ERAs): the blockade of only the endothelin receptor A (ETAR; selective antagonism) versus both ETAR and endothelin receptor B (ETBR; dual blockade). Ambrisentan, a selective ERA, and bosentan, a dual blocker, are both available for therapy. We hypothesized that there are differenc...

OBJECTIVE Exercise-induced pulmonary hypertension (ePH) may represent an early, clinically relevant phase in the spectrum of pulmonary vascular disease. The purpose of this pilot study was to describe the changes in hemodynamics and exercise capacity in patients with systemic sclerosis (SSc) spectrum-associated ePH treated with open-label daily ambrisentan. METHODS Patients were treated with ...

The following therapies may be considered medically necessary for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1):  ambrisentan (LETAIRIS®) oral;  bosentan (TRACLEER®) oral;  epoprostenol sodium (e.g., FLOLAN®) continuous IV infusion;  Iloprost (VENTAVIS®) Inhalation via nebulizer;  macitentan (OPSUMIT®) oral;  riociguat (ADEMPAS®) oral;  sildenafil citrate (e.g., REV...

Pulmonary Arterial Hypertension (PAH) is a devastating disease that, until recently, had no effective medical therapy. In 1996, a prostacyclin, epoprostenol, was approved; since then, several therapies, including prostacyclin analogues and agents that modulate other vasoactive pathways – endothelin receptor antagonists and phosphodiesterase inhibitors – have received approval. In this issue of ...